ARX788 possible new drug after t-dm1, t-dxd, tucatinib
ACE-Breast-02 Pivotal Phase 3 Study of Ambrx’s ARX788 for the Treatment of HER2 Positive Metastatic Breast Cancer Achieves Positive (INTERIM) Results
https://www.businesswire.com/news/ho...sitive-Results Emerging Data Behind 2 Antibody Drug Conjugates for Breast and https://www.targetedonc.com/view/eme...rostate-cancer "... This trial is a phase 2 study evaluating ARX788 in patients with HER2-positive metastatic breast cancer whose disease is resistant or refractory to T-DM1, and/or T-DXd, and/or tucatinib-containing regimens. ..." |
All times are GMT -7. The time now is 05:08 AM. |
Powered by vBulletin® Version 3.8.7
Copyright ©2000 - 2024, vBulletin Solutions, Inc.
Copyright HER2 Support Group 2007 - 2021